In Q4 2025, Ionis generated total revenue of 203000000, including 57000000 in net product sales and 76000000 in royalty revenue, while reporting a GAAP net loss of 229000000 and a non-GAAP net loss of 186000000 amid continued investment in commercial launches.

Ionis achieved 17% year-over-year revenue growth in Q3 2025, boosted by TRYNGOLZA product sales and increased royalty contributions. Despite a GAAP net loss of $129M, non-GAAP metrics reflected improved operational performance.

Ionis delivered strong financial results in Q2 2025, doubling revenue year-over-year and achieving $124 million in net income. Results were boosted by TRYNGOLZA product sales and a $280 million licensing payment. Non-GAAP income from operations reached $170 million, showing efficient operational execution.

Ionis reported a 10% increase in total revenue for the first quarter of 2025 compared to the same period last year, driven by higher commercial revenue from the launch of TRYNGOLZA and increased royalty revenue from SPINRAZA and WAINUA. The company also increased its full-year 2025 financial guidance.

Ionis Pharmaceuticals reported Q4 2024 revenue of $227,000,000, a 30.15% decline YoY. The company posted a net loss of $104,000,000, compared to a loss of $9,000,000 in Q4 2023. Despite these losses, Ionis exceeded its financial guidance and launched TRYNGOLZA, its first independently commercialized product.

Ionis Pharmaceuticals reported a decrease in revenue for the third quarter of 2024 compared to the same period last year, but the company is making significant progress with the launch of WAINUA and advancements in its pipeline, including regulatory submissions and positive study data.

Ionis Pharmaceuticals reported a 20% increase in revenue for Q2 2024, driven by R&D revenue and commercial launch of WAINUA. The company is advancing its pipeline with regulatory milestones for Olezarsen and Donidalorsen, and reaffirmed its 2024 financial guidance.

Ionis Pharmaceuticals reported its Q1 2024 financial results, featuring total revenues of $119 million. The company saw increased operating expenses due to investments in launching WAINUA, olezarsen, and donidalorsen. They reaffirmed their 2024 financial guidance and have $2.2 billion in cash and short-term investments.

Ionis Pharmaceuticals reported strong Q4 2023 financial results, with revenue more than doubling compared to the same period in the prior year. The company achieved several milestones, including the approval of WAINUA in the U.S. and positive Phase 3 data readouts for olezarsen and donidalorsen. Ionis is preparing regulatory submissions for FCS and HAE.

Ionis Pharmaceuticals reported Q3 2023 financial results, with total revenue of $144 million. The company is on track for potential U.S. approval of eplontersen and reported positive data from the olezarsen Phase 3 Balance study. Strategic investments in eplontersen, olezarsen, and donidalorsen contributed to increased operating expenses.

Ionis Pharmaceuticals reported a revenue increase of 40% compared to Q2 2022, driven by partner payments. The company is advancing its pipeline, with investments in eplontersen, olezarsen, and donidalorsen. They have a strong cash position of $2.4 billion.

Ionis Pharmaceuticals reported its Q1 2023 financial results, with revenue of $131 million. The company highlighted the approval of QALSODY for SOD1-ALS and the positive Phase 3 data for eplontersen in ATTRv-PN. They reaffirmed their 2023 financial guidance.

Ionis Pharmaceuticals reported Q4 2022 total revenue of $152 million and a net loss of $52 million. The company's cash, cash equivalents, and short-term investments amounted to $1.987 billion. The company submitted the eplontersen NDA in the U.S.

Ionis Pharmaceuticals reported a 20% increase in revenue for Q3 2022 compared to the same period last year, driven by significant partner payments across multiple programs. The company reaffirmed its 2022 financial guidance and increased its cash and investments guidance to approximately $2.0 billion. There was also progress in the late-stage pipeline, including positive data from the Phase 3 NEURO-TTRansform study of eplontersen.

Ionis Pharmaceuticals reported strong second quarter results with total revenues of $134 million and a net loss of $105 million on a GAAP basis. The company highlighted advancements in its pipeline, including positive Phase 3 data for eplontersen and the acceptance of the NDA for tofersen. With $2.0 billion in cash and short-term investments, Ionis is on track to achieve its 2022 financial guidance.

Ionis Pharmaceuticals reported first quarter financial results with total revenues of $142 million, a GAAP net loss of $65 million, and $2.1 billion in cash and short-term investments. The company is on track to achieve its 2022 financial guidance.

Ionis Pharmaceuticals exceeded its 2021 financial guidance with revenues of $810 million. The company is well capitalized with $2.1 billion in cash and short-term investments at year-end. They are advancing their commercial strategy and go-to-market plans for near-term commercial opportunities.

Ionis Pharmaceuticals reported $133 million in total revenues for Q3 2021. The company is well-capitalized with $2 billion in cash and investments. The company is advancing its Phase 3 pipeline and commercial readiness initiatives.

Ionis Pharmaceuticals reported $126 million in total revenues for Q2 2021. The company is on track to achieve its 2021 revenue guidance of more than $600 million. Key milestones included the completion of dosing in the tofersen Phase 3 VALOR study and full enrollment in the eplontersen Phase 3 NEURO-TTRansform study.

Ionis Pharmaceuticals reported $112 million in total revenues for Q1 2021. The company has strengthened its balance sheet with a pro forma cash of $2.1 billion. They are on track to achieve their 2021 financial guidance, reflecting investments in Ionis’ wholly owned pipeline.

Ionis Pharmaceuticals reported Q4 2020 financial results, achieving its 2020 financial guidance with $729 million in total revenues for the year. The company is focused on maximizing the value of its pipeline by commercializing wholly owned medicines, with key upcoming catalysts including data from multiple programs and Phase 3 tofersen data. Ionis ended the year with a strong balance sheet, holding $1.9 billion in cash.

Ionis Pharmaceuticals reported a net loss of $31 million on a GAAP basis but achieved a net income of $5 million on a non-GAAP basis for Q3 2020. The company saw quarter-over-quarter revenue growth, driven by SPINRAZA royalties, increased product sales from TEGSEDI and WAYLIVRA, and advancements in partnered R&D programs. Ionis maintained a strong balance sheet with $2.3 billion in cash.

Ionis Pharmaceuticals reported a net loss of $32 million on a GAAP basis but achieved net income of $8 million on a non-GAAP basis. The company saw growth in commercial and R&D revenues and maintained a strong cash position of over $2.3 billion.

Ionis Pharmaceuticals reported its Q1 2020 financial results, demonstrating strong performance in commercial medicines, particularly SPINRAZA, and advancements in its late-stage pipeline. The company reaffirmed its 2020 financial guidance, expecting to end the year meaningfully profitable, supported by commercial and R&D revenue. With a strong cash position of $2.4 billion, Ionis is well-capitalized to execute its strategic priorities.

Ionis Pharmaceuticals reported strong fourth-quarter and full-year 2019 financial results, with revenues nearly doubling due to SPINRAZA's performance and increased R&D revenue. The company achieved profitability, increased its cash position, and invested in its pipeline and technology.